FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024069889> ?p ?o ?g. }

• W2024069889 endingPage "752" @default.
• W2024069889 startingPage "743" @default.
• W2024069889 abstract "Epidemiological data suggest an important role of vitamin D signaling in cancer development and progression, and experimental studies demonstrate that the active vitamin D metabolite 1α, 25-dihydroxyvitamin D₃ (1,25D₃) has broad spectrum antitumor activity. Hypercalcemia has often been suggested to limit the clinical application of these data. The 14-epi-analog of 1,25D₃, inecalcitol [19-nor-14-epi-23-yne-1,25-(OH)₂D₃; TX522], was developed to have superagonistic antitumor activities but low hypercalcemia potential. We examined the antitumor activity of inecalcitol and the underlying mechanisms in a murine squamous cell carcinoma (SCC) model system. In vitro, compared with 1,25D₃, inecalcitol showed enhanced vitamin D receptor (VDR)-mediated transcriptional activity. Inecalcitol suppressed SCC cell proliferation in a dose-dependent manner with an IC₅₀ value 30 times lower than that of 1,25D₃. Both inecalcitol and 1,25D₃ induced a comparable level of G₀/G₁ cell cycle arrest in SCC cells. The level of apoptosis induced by inecalcitol was markedly higher than that of 1,25D₃. Apoptosis was mediated through the activation of the caspase 8/10- caspase 3 pathway. Further, inecalcitol markedly inhibited the mRNA and protein expression of c-IAP1 and XIAP compared with 1,25D₃. In vivo, inecalcitol inhibits SCC tumor growth in a dose-dependent fashion. Notably, inecalcitol induced a significantly higher level of apoptosis in the SCC xenograft model. While in vitro inecalcitol demonstrates apparent enhanced VDR binding and antiproliferative effects compared to 1,25D₃, in vivo these advantages disappear; at doses of inecalcitol that have equivalent antitumor effects, similar hypercalcemia is seen. This may be explained by the pharmacokinetics of 1,25D₃ vs. inecalcitol and attributed to the much shorter serum half-life of inecalcitol.We show that inecalcitol has potent antitumor activity in the SCC model system, and this is associated with a strong induction of apoptosis. These findings support the further development of inecalcitol in cancer treatment." @default.
• W2024069889 created "2016-06-24" @default.
• W2024069889 creator A5003125279 @default.
• W2024069889 creator A5012147181 @default.
• W2024069889 creator A5019706619 @default.
• W2024069889 creator A5042546997 @default.
• W2024069889 creator A5065161783 @default.
• W2024069889 creator A5081220639 @default.
• W2024069889 creator A5089311549 @default.
• W2024069889 date "2013-03-01" @default.
• W2024069889 modified "2023-09-29" @default.
• W2024069889 title "Inecalcitol, an analog of 1,25D₃, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system" @default.
• W2024069889 cites W1990389642 @default.
• W2024069889 cites W2002176238 @default.
• W2024069889 cites W2005441877 @default.
• W2024069889 cites W2016448652 @default.
• W2024069889 cites W2026644677 @default.
• W2024069889 cites W2031646904 @default.
• W2024069889 cites W2058645214 @default.
• W2024069889 cites W2059937375 @default.
• W2024069889 cites W2064866491 @default.
• W2024069889 cites W2070004921 @default.
• W2024069889 cites W2077575239 @default.
• W2024069889 cites W2084198387 @default.
• W2024069889 cites W2084369338 @default.
• W2024069889 cites W2106402853 @default.
• W2024069889 cites W2112198605 @default.
• W2024069889 cites W2114578836 @default.
• W2024069889 cites W2139813111 @default.
• W2024069889 cites W2141326395 @default.
• W2024069889 cites W2144702175 @default.
• W2024069889 cites W2155216078 @default.
• W2024069889 cites W2168011238 @default.
• W2024069889 doi "https://doi.org/10.4161/cc.23846" @default.
• W2024069889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3610722" @default.
• W2024069889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23388458" @default.
• W2024069889 hasPublicationYear "2013" @default.
• W2024069889 type Work @default.
• W2024069889 sameAs 2024069889 @default.
• W2024069889 citedByCount "36" @default.
• W2024069889 countsByYear W20240698892013 @default.
• W2024069889 countsByYear W20240698892014 @default.
• W2024069889 countsByYear W20240698892015 @default.
• W2024069889 countsByYear W20240698892016 @default.
• W2024069889 countsByYear W20240698892017 @default.
• W2024069889 countsByYear W20240698892018 @default.
• W2024069889 countsByYear W20240698892019 @default.
• W2024069889 countsByYear W20240698892020 @default.
• W2024069889 countsByYear W20240698892021 @default.
• W2024069889 countsByYear W20240698892022 @default.
• W2024069889 countsByYear W20240698892023 @default.
• W2024069889 crossrefType "journal-article" @default.
• W2024069889 hasAuthorship W2024069889A5003125279 @default.
• W2024069889 hasAuthorship W2024069889A5012147181 @default.
• W2024069889 hasAuthorship W2024069889A5019706619 @default.
• W2024069889 hasAuthorship W2024069889A5042546997 @default.
• W2024069889 hasAuthorship W2024069889A5065161783 @default.
• W2024069889 hasAuthorship W2024069889A5081220639 @default.
• W2024069889 hasAuthorship W2024069889A5089311549 @default.
• W2024069889 hasBestOaLocation W20240698891 @default.
• W2024069889 hasConcept C105696609 @default.
• W2024069889 hasConcept C124490489 @default.
• W2024069889 hasConcept C134018914 @default.
• W2024069889 hasConcept C150903083 @default.
• W2024069889 hasConcept C179639408 @default.
• W2024069889 hasConcept C190283241 @default.
• W2024069889 hasConcept C207001950 @default.
• W2024069889 hasConcept C25311885 @default.
• W2024069889 hasConcept C29537977 @default.
• W2024069889 hasConcept C31573885 @default.
• W2024069889 hasConcept C33195913 @default.
• W2024069889 hasConcept C502942594 @default.
• W2024069889 hasConcept C55493867 @default.
• W2024069889 hasConcept C62112901 @default.
• W2024069889 hasConcept C86803240 @default.
• W2024069889 hasConcept C98274493 @default.
• W2024069889 hasConcept C98424977 @default.
• W2024069889 hasConceptScore W2024069889C105696609 @default.
• W2024069889 hasConceptScore W2024069889C124490489 @default.
• W2024069889 hasConceptScore W2024069889C134018914 @default.
• W2024069889 hasConceptScore W2024069889C150903083 @default.
• W2024069889 hasConceptScore W2024069889C179639408 @default.
• W2024069889 hasConceptScore W2024069889C190283241 @default.
• W2024069889 hasConceptScore W2024069889C207001950 @default.
• W2024069889 hasConceptScore W2024069889C25311885 @default.
• W2024069889 hasConceptScore W2024069889C29537977 @default.
• W2024069889 hasConceptScore W2024069889C31573885 @default.
• W2024069889 hasConceptScore W2024069889C33195913 @default.
• W2024069889 hasConceptScore W2024069889C502942594 @default.
• W2024069889 hasConceptScore W2024069889C55493867 @default.
• W2024069889 hasConceptScore W2024069889C62112901 @default.
• W2024069889 hasConceptScore W2024069889C86803240 @default.
• W2024069889 hasConceptScore W2024069889C98274493 @default.
• W2024069889 hasConceptScore W2024069889C98424977 @default.
• W2024069889 hasIssue "5" @default.
• W2024069889 hasLocation W20240698891 @default.
• W2024069889 hasLocation W20240698892 @default.
• W2024069889 hasLocation W20240698893 @default.

• next